KAIROS PHARMA LTD Financials
This page shows KAIROS PHARMA LTD (KAPA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
KAIROS PHARMA LTD passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, KAIROS PHARMA LTD generates $1.52 in operating cash flow (-$4.0M OCF vs -$2.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
KAIROS PHARMA LTD earns $-66.9 in operating income for every $1 of interest expense (-$2.3M vs $35K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
KAIROS PHARMA LTD reported -$2.6M in net income in fiscal year 2024. This represents a decrease of 43.7% from the prior year.
KAIROS PHARMA LTD earned $-0.23 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 35.3% from the prior year.
KAIROS PHARMA LTD held $1.3M in cash against $0 in long-term debt as of fiscal year 2024.
KAIROS PHARMA LTD had 14M shares outstanding in fiscal year 2024. This represents an increase of 30.0% from the prior year.
KAIROS PHARMA LTD's ROE was -54.5% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 141.7 percentage points from the prior year.
KAIROS PHARMA LTD invested $414K in research and development in fiscal year 2024. This represents an increase of 404.9% from the prior year.
KAPA Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $608K+22.6% | $496K+0.6% | $493K | N/A | $14K-77.8% | $63K-61.8% | $165K | N/A |
| SG&A Expenses | $827K-13.9% | $960K+24.2% | $773K | N/A | $369K+132.1% | $159K+30.3% | $122K | N/A |
| Operating Income | -$1.4M+1.4% | -$1.5M-15.0% | -$1.3M | N/A | -$383K-72.5% | -$222K+22.6% | -$287K | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | $12K0.0% | $12K-25.0% | $16K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$1.4M+1.7% | -$1.4M-12.7% | -$1.3M | N/A | -$1.0M-313.8% | -$253K+21.7% | -$323K | N/A |
| EPS (Diluted) | $-0.07+12.5% | $-0.080.0% | $-0.08 | N/A | $-0.10-400.0% | $-0.02+33.3% | $-0.03 | N/A |
KAPA Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.1M+20.9% | $6.7M-15.9% | $7.9M+37.6% | $5.8M+15.3% | $5.0M | N/A | N/A | $965K |
| Current Assets | $6.7M+37.5% | $4.8M-20.0% | $6.0M+45.1% | $4.2M-12.1% | $4.7M | N/A | N/A | $101K |
| Cash & Equivalents | $5.6M+83.8% | $3.0M-16.1% | $3.6M+184.3% | $1.3M-60.5% | $3.2M+15219.0% | $21K-47.5% | $40K-57.0% | $93K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $402K-40.5% | $676K-16.0% | $805K-18.9% | $992K-40.7% | $1.7M | N/A | N/A | $3.0M |
| Current Liabilities | $402K-40.5% | $676K-16.0% | $805K-18.9% | $992K-40.7% | $1.7M | N/A | N/A | $2.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $7.7M+27.8% | $6.0M-15.9% | $7.1M+49.3% | $4.8M+43.3% | $3.3M+225.5% | -$2.7M-10.5% | -$2.4M-15.5% | -$2.1M |
| Retained Earnings | -$12.9M-12.2% | -$11.5M-14.1% | -$10.1M-14.3% | -$8.8M-12.5% | -$7.8M | N/A | N/A | -$6.2M |
KAPA Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$838K-4.1% | -$805K-12.7% | -$714K+60.4% | -$1.8M+10.7% | -$2.0M-1102.4% | -$168K-566.7% | $36K-45.5% | $66K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $3.4M+1415.2% | $223K-92.7% | $3.1M+2253.5% | -$142K-102.7% | $5.2M+3400.7% | $149K+267.4% | -$89K-23.6% | -$72K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
KAPA Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -18.2%+5.5pp | -23.7%-6.0pp | -17.7% | N/A | -31.4%-41.0pp | 9.5%-3.9pp | 13.5% | N/A |
| Return on Assets | -17.3%+4.0pp | -21.3%-5.4pp | -15.9% | N/A | -20.9% | N/A | N/A | N/A |
| Current Ratio | 16.56+9.4 | 7.16-0.4 | 7.52+3.3 | 4.20+1.4 | 2.84 | N/A | N/A | 0.04 |
| Debt-to-Equity | 0.05-0.1 | 0.110.0 | 0.11-0.1 | 0.21-0.3 | 0.50 | N/A | N/A | -1.46 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is KAIROS PHARMA LTD profitable?
No, KAIROS PHARMA LTD (KAPA) reported a net income of -$2.6M in fiscal year 2024.
What is KAIROS PHARMA LTD's earnings per share (EPS)?
KAIROS PHARMA LTD (KAPA) reported diluted earnings per share of $-0.23 for fiscal year 2024. This represents a -35.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is KAIROS PHARMA LTD's return on equity (ROE)?
KAIROS PHARMA LTD (KAPA) has a return on equity of -54.5% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is KAIROS PHARMA LTD's operating cash flow?
KAIROS PHARMA LTD (KAPA) generated -$4.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are KAIROS PHARMA LTD's total assets?
KAIROS PHARMA LTD (KAPA) had $5.8M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does KAIROS PHARMA LTD spend on research and development?
KAIROS PHARMA LTD (KAPA) invested $414K in research and development during fiscal year 2024.
How many shares does KAIROS PHARMA LTD have outstanding?
KAIROS PHARMA LTD (KAPA) had 14M shares outstanding as of fiscal year 2024.
What is KAIROS PHARMA LTD's current ratio?
KAIROS PHARMA LTD (KAPA) had a current ratio of 4.20 as of fiscal year 2024, which is generally considered healthy.
What is KAIROS PHARMA LTD's debt-to-equity ratio?
KAIROS PHARMA LTD (KAPA) had a debt-to-equity ratio of 0.21 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is KAIROS PHARMA LTD's return on assets (ROA)?
KAIROS PHARMA LTD (KAPA) had a return on assets of -45.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is KAIROS PHARMA LTD's cash runway?
Based on fiscal year 2024 data, KAIROS PHARMA LTD (KAPA) had $1.3M in cash against an annual operating cash burn of $4.0M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is KAIROS PHARMA LTD's Piotroski F-Score?
KAIROS PHARMA LTD (KAPA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are KAIROS PHARMA LTD's earnings high quality?
KAIROS PHARMA LTD (KAPA) has an earnings quality ratio of 1.52x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can KAIROS PHARMA LTD cover its interest payments?
KAIROS PHARMA LTD (KAPA) has an interest coverage ratio of -66.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.